• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

EPAD has been featured in the inaugural ADDI newsletter

2021-07-01News

On 1 July, the Alzheimer’s Disease Data Initiative (ADDI) released its first ever newsletter, in which EPAD is featured as a key partner and the first project to place its entire dataset onto the Alzheimer’s Disease Workbench.

From January 2015 until February 2020, the EPAD Longitudinal Cohort Study (LCS) screened over 2,000 participants across nine European countries to collect a wide range of cognitive, clinical, neuroimaging and biomarker data. A total of 2,096 participants were screened. From these 2,096 participants, EPAD followed up with 1,225 after one year, 421 after two years and 121 after three years. As the project progressed, four datasets have freely been made available ensuring the use of the data for the Alzheimer’s disease research community worldwide.

“As a participant in the EPAD LCS it is very satisfying to know that my data is being made widely available to researchers. To know that this quality assured data will be used internationally reassures me that my involvement in this project will assist in the unravelling of the mystery that is Alzheimer’s disease,” said Malcolm Smith, Chair of the EPAD Scotland participants panel.

The latest and final EPAD dataset called Version.IMI. (V.IMI) is now available in the AD Workbench and will provide even greater value to the global neuroscience research community. All the data collected and processed during the IMI period of EPAD have been included in this V.IMI release.

“Prospective collection of information and samples in EPAD has been a major scientific effort to expand the frontiers of our knowledge on the natural history of Alzheimer’s in its predementia stages. But now in the AD Workbench, this dataset will be findable, accessible, interoperable and reusable (according to the FAIR principles) to other bona fide researchers for it to exert its full, intended impact to fight Alzheimer’s disease,” said Juan Domingo Gispert, principal investigator of the EPAD study in Barcelona and head of the Neuroimaging group of the Barcelonaβeta Brain Research Center (BBRC).

EPAD members are pleased that this incredibly rich data source, including data that have been collected annually from research participants throughout their participation in the LCS, has been incorporated into the AD Workbench. It is an important step in continuing to share the LCS data in the long-term and ensuring that this valuable resource is used by the research community to generate as much knowledge as possible. The ADDI platform will provide a crucial acceleration in scientific breakthroughs on the causes, diagnosis, and prevention of Alzheimer’s disease.

“At the heart of the EPAD Programme was an explicit commitment, responsibility and obligation to ensure that the time and effort of research participants and researchers yielded the highest quality outputs of knowledge. The global visibility and ease of access and research which ADDI provides helps us to achieve our objective. Moreover, having been involved for the last few years in the design of the AD Workbench it stands to reason that this platform is absolutely perfect for our needs and we are honoured and delighted to be the first project to place our entire dataset onto the work bench. We expect that in the years ahead, new data being collected from EPAD and other programmes from across Europe and the World will utilise the ADDI workbench making ‘interoperability’ a real success,” said Craig Ritchie, Project Coordinator of the EPAD project.

You can read the ADDI newsletter here.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
New paper on the affordances of clinical research participation
2022-01-14
ADDI celebrates one year of achievements
2021-11-17
Latest News
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
    2022-03-10
  • New paper on the affordances of clinical research participation
    2022-01-14
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Registration is now open for the upcoming #NeuroToolKit Data Hackathon! Join fellow experts and investigate biomarkers in #Alzheimers disease. You'll work with @IMI_EPAD datasets by utilizing @AlzData resources. For more information: ep-ad.org/addi-neurotool… twitter.com/IMI_EPAD/statu…

reply retweet favorite
6:56 am · 2022-05-18
Twitter
EPAD
EPAD
@IMI_EPAD

📢 Four abstracts with @IMI_EPAD data have been accepted for #AAIC22, including 3 posters & 1 oral presentation! Looking forward to meeting you in San Diego! @LuigiLorenzini1 @GregorySarah @fpmaragall @amsterdamumc @CenDemPrevent twitter.com/alzassociation…

reply retweet favorite
10:45 am · 2022-04-28
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Research Participant Panel has been established to give participants an active role in influencing the design, conduct and reporting of research. Want to know more? Watch this recording. #31AEC @AlzheimerEurope @IMI2_NEURONET @CenDemPrevent youtu.be/GObdDorTOE0?t=…

reply retweet favorite
6:42 am · 2022-04-20
Twitter
EPAD
EPAD
@IMI_EPAD

Listen to @GregorySarah from @CenDemPrevent talking about the associations between stressful life events, #Alzheimer's disease biomarkers and cognition in the @IMI_EPAD Longitudinal Cohort Study at the @AlzheimerEurope conference #31AEC. youtu.be/loZSphK4s9g

reply retweet favorite
9:45 am · 2022-04-11
Twitter
EPAD
EPAD
@IMI_EPAD

We are delighted to announce that the first study participant for the @IMI_EPAD Scotland study was seen today! It is the first national initiative to have started study recruitment. @craig_ritchie68 @CenDemPrevent For more info, visit our website⤵️ ep-ad.org/first-national… pic.twitter.com/4Z46mokA88

reply retweet favorite
12:44 pm · 2022-04-07
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT